TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
Clinical trial NCT07271992 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07271992
- Sponsor
- First Hospital of China Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-15
- Primary completion
- 2030-12-14
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.